GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Liabilities-to-Assets

Accelerated Pharma (Accelerated Pharma) Liabilities-to-Assets : 36.31 (As of Mar. 2017)


View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Accelerated Pharma's Total Liabilities for the quarter that ended in Mar. 2017 was $7.19 Mil. Accelerated Pharma's Total Assets for the quarter that ended in Mar. 2017 was $0.20 Mil. Therefore, Accelerated Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2017 was 36.31.


Accelerated Pharma Liabilities-to-Assets Historical Data

The historical data trend for Accelerated Pharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Liabilities-to-Assets Chart

Accelerated Pharma Annual Data
Trend Dec14 Dec15 Dec16
Liabilities-to-Assets
1.35 6.78 44.56

Accelerated Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Liabilities-to-Assets Get a 7-Day Free Trial - 42.58 28.20 44.56 36.31

Competitive Comparison of Accelerated Pharma's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerated Pharma's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Liabilities-to-Assets falls into.



Accelerated Pharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Accelerated Pharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Liabilities-to-Assets (A: Dec. 2016 )=Total Liabilities/Total Assets
=6.55/0.147
=44.56

Accelerated Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2017 is calculated as

Liabilities-to-Assets (Q: Mar. 2017 )=Total Liabilities/Total Assets
=7.189/0.198
=36.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerated Pharma  (NAS:ACCP) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Accelerated Pharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerated Pharma (Accelerated Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Website
Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines